DBV Technologies (DBVT) Assets Average (2016 - 2026)
DBV Technologies (DBVT) posted quarterly Assets Average of $244.8 million for Q2 2026, up 152.38% year-on-year from $97.0 million in Q2 2025, and down 2.1% on a QoQ basis from $250.0 million in Q1 2026.
DBV Technologies (DBVT) Assets Average (2016 - 2026) Analysis & Trends
DBV Technologies (DBVT) has reported Assets Average for 10 consecutive years, with $244.8 million the latest figure, recorded in Q2 2026.
- Quarterly Assets Average rose 152.38% year-over-year to $244.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $244.8 million (up 152.38% YoY) and the FY2025 annual result came in at $149.7 million, up 20.4% from the prior year.
- Assets Average eased to $244.8 million in Q2 2026 per DBVT's latest filing, from $250.0 million in the prior quarter.
- Over the last five years, Assets Average for DBVT reached as high as $266.5 million in Q3 2022 and fell as low as $58.1 million in Q1 2025.
- A 5-year average of $173.8 million and a median of $179.2 million in 2023 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2025 — Assets Average slumped 64.66% — and 2026, when it surged 330.3%.
- Year by year, Assets Average stood at $247.3 million in 2022, then fell by 24.64% to $186.4 million in 2023, then sank by 57.42% to $79.4 million in 2024, then surged by 116.87% to $172.1 million in 2025, then surged by 42.24% to $244.8 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $244.8 million, $250.0 million, and $172.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 303.40 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 65.01 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 8.37 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 41.64 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 26.06 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 40.71 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 795.91 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.30 Bn |
| 10 | DBV Technologies | 267.50 Mn | 92.60 Mn | - | 244.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 244.80 Mn |
| Mar 31, 2026 | 250.05 Mn |
| Dec 31, 2025 | 172.10 Mn |
| Sep 30, 2025 | 126.96 Mn |
| Jun 30, 2025 | 97.00 Mn |
| Mar 31, 2025 | 58.11 Mn |
| Dec 31, 2024 | 79.36 Mn |
| Sep 30, 2024 | 103.62 Mn |
| Jun 30, 2024 | 130.04 Mn |
| Mar 31, 2024 | 164.44 Mn |
| Dec 31, 2023 | 186.38 Mn |
| Sep 30, 2023 | 203.65 Mn |
| Jun 30, 2023 | 225.22 Mn |
| Mar 31, 2023 | 239.72 Mn |
| Dec 31, 2022 | 247.32 Mn |
| Sep 30, 2022 | 266.55 Mn |
| Jun 30, 2022 | 201.28 Mn |
| Mar 31, 2022 | 132.15 Mn |
| Dec 31, 2021 | 158.82 Mn |
| Sep 30, 2021 | 185.75 Mn |